{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:40Z","timestamp":1767134920264,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd007003.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"reference-count":107,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007003.pub3","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T07:12:04Z","timestamp":1682406724000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interventions for dialysis patients with hepatitis C virus (HCV) infection"],"prefix":"10.1002","volume":"2023","author":[{"given":"Attur Ravindra","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Kasturba Medical College Manipal, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indu Ramachandra","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Kasturba Medical College Manipal, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar Prasad","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Kasturba Medical College Manipal, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eti","family":"Rajwar","sequence":"additional","affiliation":[{"name":"Public Health Evidence South Asia (PHESA); Prasanna School of Public Health, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumika T","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Public Health Evidence South Asia (PHESA); Prasanna School of Public Health, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekumaran","family":"Nair N","sequence":"additional","affiliation":[{"name":"Department of Medical Biometrics & Informatics (Biostatistics); Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) (Institution of National Importance Under Ministry of Health and Family Welfare, Government of India); Dhanvantri Nagar India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Kasturba Medical College Manipal, Manipal Academy of Higher Education; Manipal India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageswara P","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Yashoda Hospitals; Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Suvarna","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; JSS Medical College; Mysore India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0001|cit1","first-page":"110","article-title":"Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with a-interferon (IFN) followed by kidney transplantation [abstract no: M221]","volume":"17","author":"Alfurayh","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD007003.pub3-BIB0002|cit2","first-page":"A106","article-title":"Randomised controlled trial of interferon-alpha (IFNalpha) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]","volume":"15","author":"Alfurayh","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD007003.pub3-BIB0003|cit3","first-page":"255A","article-title":"IFN-alpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]","volume":"11","author":"Alfurayh","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0004|cit4","first-page":"80","article-title":"Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309]","volume":"16","author":"Campistol","year":"1996","journal-title":"Nefrolog\u00eda"},{"issue":"11","key":"10.1002\/14651858.CD007003.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/ndt\/14.11.2704","article-title":"Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment","volume":"14","author":"Campistol","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007003.pub3-BIB0006|cit6","first-page":"242A","article-title":"Impact of grazoprevir plus elbasvir on health-related quality of life in patients with hepatitis C virus genotype 1 infection and chronic kidney disease stages 4 and 5 [abstract no: TH-PO667]","volume":"26","author":"Arduino","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007003.pub3-BIB0007|cit7","first-page":"65","article-title":"Elbasvir (EBR)\/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4\/5: final results of the C-SURFER phase 3 study [abstract]","volume":"31","author":"Barr","year":"2016","journal-title":"Journal of Gastroenterology & Hepatology"},{"issue":"Suppl 221","key":"10.1002\/14651858.CD007003.pub3-BIB0008|cit8","first-page":"23S","article-title":"Elbasvir\/Grazoprevir (EBR\/GZR) treatment of hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4\/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study [abstract]","volume":"146","author":"Bruchfeld","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Bruchfeld","year":"2017","journal-title":"The Lancet. Gastroenterology & Hepatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007003.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"iii156","DOI":"10.1093\/ndt\/gfv174.02","article-title":"C-surfer: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: FP267]","volume":"30","author":"Bruchfeld","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007003.pub3-BIB0011|cit11","first-page":"B5","article-title":"Grazoprevir(GZR)\/elbasvir (EBR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4\/5:final results of the C -SURFER phase 3 study [abstract no: SA-PO1100]","volume":"26","author":"Roth","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007003.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30156-2","article-title":"C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract no: LP02]","volume":"62","author":"Roth","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"10003","key":"10.1002\/14651858.CD007003.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [Erratum in: Lancet. 2015 Nov 7;386(10006):1824; PMID: 26843312]","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"4 (Pt 2)","key":"10.1002\/14651858.CD007003.pub3-BIB0014|cit14","first-page":"116A","article-title":"A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]","volume":"22","author":"Fernandez","year":"1995","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD007003.pub3-BIB0015|cit15","first-page":"1446","article-title":"A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]","volume":"7","author":"Fernandez","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2893.1997.tb00213.x","article-title":"A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection","volume":"4","author":"Fernandez","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0017|cit17","first-page":"1096A","article-title":"Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract no: 1851]","volume":"58","author":"Liu","year":"2013","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD007003.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0019|cit19","first-page":"993A","article-title":"Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract no: 1722]","volume":"56","author":"Liu","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007003.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S0168-8278(08)61001-6","article-title":"Low-dose peginterferon alfa-2A (40KD) (PEGASYS\u00ae) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]","volume":"48","author":"Peck-Radosavljevic","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2010.10.018","article-title":"Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease","volume":"9","author":"Peck-Radosavljevic","year":"2011","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S0168-8278(07)62226-0","article-title":"Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]","volume":"46","author":"Peck-Radosavljevic","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000046646","article-title":"Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C","volume":"21","author":"Huraib","year":"2001","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/gut.2007.133884","article-title":"Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study","volume":"57","author":"Liu","year":"2008","journal-title":"Gut"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0026|cit26","first-page":"703","article-title":"Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract no: 1281]","volume":"42","author":"Luxon","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","article-title":"Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C","volume":"21","author":"Russo","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0028|cit28","first-page":"399A","article-title":"A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract no: 540]","volume":"40","author":"Russo","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.14309\/00000434-201310001-00513","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract no: 513]","volume":"108","author":"Basu","year":"2013","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1016\/S0016-5085(13)63533-7","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no: 517]","volume":"144","author":"Basu","year":"2013","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD007003.pub3-BIB0031|cit31","first-page":"S362","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]","volume":"28","author":"Basu","year":"2014","journal-title":"Surgical Endoscopy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0032|cit32","first-page":"S244","article-title":"Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract no: P-298]","volume":"20","author":"Basu","year":"2014","journal-title":"Liver Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60069-0","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]","volume":"58","author":"Basu","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007003.pub3-BIB0034|cit34","first-page":"416","article-title":"Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract no: A2147]","volume":"12","author":"Tuglular","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0168-8278(05)80248-X","article-title":"Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha","volume":"18","author":"Ellis","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"8410","key":"10.1002\/14651858.CD007003.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(84)91153-X","article-title":"Prevention of non-A, non-B hepatitis in haemodialysis patients by hepatitis B immunoglobulin","volume":"2","author":"Simon","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Muzammil M Tahir M Ullah N Arif MM Rasheeq T Ather MM Comparison of efficacy of daily sofosbuvir and declatasvir with alternate day sofosbuvir and declatasvir in hepatitis C patients on hemodialysis in Pakistani population Pakistan Journal of Medical & Health Sciences 2022 16 8 264 6 10.53350\/pjmhs22168264","DOI":"10.53350\/pjmhs22168264"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi","year":"2018","journal-title":"Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0040|cit40","first-page":"181","article-title":"Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection","volume":"4","author":"Alavian","year":"2010","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.14.255","article-title":"Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C","volume":"14","author":"Ayaz","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0043|cit43","first-page":"1447","volume-title":"Harrison's Principles of Internal Medicine","volume":"1","author":"Baden","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","article-title":"Hepatitis C infection is acquired pre-ESRD","volume":"45","author":"Bergman","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub3-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006420.pub2","article-title":"Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units","author":"Bravo Zu\u00f1iga","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"287\u201392","DOI":"10.1046\/j.1365-2893.2001.00300.x","article-title":"Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study","volume":"8","author":"Bruchfeld","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Bruchfeld","year":"2017","journal-title":"The Lancet. Gastroenterology & Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.meg.0000231752.50587.ae","article-title":"Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?","volume":"18","author":"Burra","year":"2006","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"10179","key":"10.1002\/14651858.CD007003.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000080883","article-title":"Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure","volume":"47","author":"Chandra","year":"2004","journal-title":"Intervirology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Chaparro M Trapero-Marugan M Moreno-Otero R Gisbert JP Azathioprine plus ribavirin treatment and pancytopenia Alimentary Pharmacology & Therapeutics 2009 30 9 962 3 19807727","DOI":"10.1111\/j.1365-2036.2009.04109.x"},{"issue":"4902","key":"10.1002\/14651858.CD007003.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts","volume":"1","author":"Cruzado","year":"2001","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0054|cit54","first-page":"2542","volume-title":"Harrison's Principles of Internal Medicine","volume":"2","author":"Dienstag","year":"2012"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0055|cit55","first-page":"2578","volume-title":"Harrison's Principles of Internal Medicine","volume":"2","author":"Dienstag","year":"2012"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0056|cit56","first-page":"2591","volume-title":"Harrison's Principles of Internal Medicine","author":"Dienstag","year":"2022"},{"issue":"11-12","key":"10.1002\/14651858.CD007003.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","article-title":"Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients","volume":"18","author":"Fabrizi","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"11-12","key":"10.1002\/14651858.CD007003.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2893.2008.00990.x","article-title":"Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2007.00907.x","article-title":"Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1002\/14651858.CD007003.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clinre.2018.10.009","article-title":"Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis","volume":"43","author":"Fabrizi","year":"2019","journal-title":"Clinics & Research in Hepatology & Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD007003.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2893.1999.t01-1-6120131.x","article-title":"Hepatitis C viral quasispecies","volume":"6","author":"Gomez","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"7650","key":"10.1002\/14651858.CD007003.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ndt\/11.supp4.54","article-title":"Glomerular disease during HCV infection in renal transplantation","volume":"11 Suppl 4","author":"Hammoud","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0070|cit70","unstructured":"Hassan AA Khalil R Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusion, and liver disease Saudi Journal of Kidney Diseases & Transplantation 2000 11 1 72 3 18209303"},{"issue":"1S Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1097\/MEG.0000000000002173","article-title":"Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase","volume":"33","author":"Hayes","year":"2021","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"7414","key":"10.1002\/14651858.CD007003.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0073|cit73","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0074|cit74","first-page":"20","article-title":"Interferon: mechanisms of action and clinical value","volume":"2","author":"Houglum","year":"1983","journal-title":"Clinical Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12882-020-1687-1","article-title":"Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease","volume":"21","author":"Iliescu","year":"2020","journal-title":"BMC Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD007003.pub3-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012143.pub2","article-title":"Direct-acting antivirals for chronic hepatitis C","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of direct-acting antiviral treatment with mortality among Medicare beneficiaries with hepatitis C","volume":"3","author":"Kalidindi","year":"2020","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"8","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","year":"2018","journal-title":"Kidney International Supplements"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0080|cit80","first-page":"257","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease","volume":"4","author":"Lawitz","year":"2019","journal-title":"KI Reports"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","article-title":"Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis","volume":"37","author":"Li","year":"2017","journal-title":"Liver International"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00007890-199504150-00030","article-title":"Interferon-alpha-induced acute renal allograft rejection","volume":"59","author":"Magnone","year":"1995","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e0246594","DOI":"10.1371\/journal.pone.0246594","article-title":"An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease","volume":"16","author":"Majd Jabbari","year":"2021","journal-title":"PloS ONE"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications [Erratum in: Gastroenterology. 2021 Jul;161(1):377; PMID: 30817897]","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","article-title":"Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy","volume":"11","author":"Nakayama","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5386","key":"10.1002\/14651858.CD007003.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007003.pub3-BIB0088|cit88","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"The Lancet. Gastroenterology & Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","article-title":"Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents","volume":"19","author":"Poordad","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000117573","article-title":"Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures","volume":"28","author":"Rahnavardi","year":"2008","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub3-BIB0092|cit92","first-page":"247","article-title":"The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation","volume":"11","author":"Rostami","year":"2011","journal-title":"Hepatitis Monthly"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","article-title":"Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety","volume":"98","author":"Russo","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0094|cit94","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0095|cit95","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"14332","DOI":"10.1038\/s41598-020-71205-5","article-title":"Efficacy and safety of Sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis","volume":"10","author":"Shehadeh","year":"2020","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1002\/14651858.CD007003.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0099|cit99","volume-title":"USP D1. Volume 1, Drug Information for the Health Care Professional","year":"2006"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0101|cit101","unstructured":"World Health Organization (\u200e2016)\u200e. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis https:\/\/apps.who.int\/iris\/handle\/10665\/246177"},{"issue":"8565","key":"10.1002\/14651858.CD007003.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(87)91422-X","article-title":"Inhibition of theophylline metabolism by interferon","volume":"2","author":"Williams","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007003.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2165\/00003088-199019050-00003","article-title":"Clinical pharmacokinetics of interferons","volume":"19","author":"Wills","year":"1990","journal-title":"Clinical Pharmacokinetics"},{"issue":"22","key":"10.1002\/14651858.CD007003.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","article-title":"Clinical features of adverse reactions associated with telbivudine","volume":"14","author":"Zhang","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007003.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007003","article-title":"Interventions for dialysis patients with hepatitis C virus (HCV) infection","author":"Prabhu","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub3-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007003.pub2","article-title":"Interventions for dialysis patients with hepatitis C virus (HCV) infection","author":"Prabhu","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T08:33:29Z","timestamp":1729845209000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007003.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007003.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}